MiNK Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: Yahoo! Finance
dosing imminently after prior phase I/II data showed dosing up to 1 billion cells was well tolerated with clinical signals (including rapid extubation, pathogen clearance) and a reported 70% survival versus ~10% in hospital controls; initial clinical data are expected in the second half of 2026 Updated SITC data in heavily pretreated, checkpoint-refractory solid tumors reported a median overall survival 23 months with complete remissions beyond two years across multiple tumor types, alongside signs of coordinated immune activation and controlled cytokine increases without systemic toxicity. MiNK ended 2025 with $13.4 million in cash and has since raised an additional $3 million via its ATM (extending runway through 2026), posted a full-year net loss of $12.5 million , and plans to activate a GVHD trial supported by non-dilutive NIH/NIAID and Mary Goos funding with dosing targeted in the first half of 2026. Interested in MiNK Therapeutics, Inc.? Here are five stocks we like bette
Show less
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell TherapyGlobeNewswire
- MiNK Therapeutics (INKT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference [TheStreet.com]TheStreet.com
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International ConferenceGlobeNewswire
INKT
Earnings
- 3/31/26 - Beat
INKT
Analyst Actions
- 4/1/26 - HC Wainwright
INKT
Sec Filings
- 3/31/26 - Form 10-K
- 3/31/26 - Form 8-K
- 3/27/26 - Form 8-K
- INKT's page on the SEC website